{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:09:21Z","timestamp":1790438961179,"version":"4.1.0"},"reference-count":49,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T00:00:00Z","timestamp":1542672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272200700016I"],"award-info":[{"award-number":["HHSN272200700016I"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["RO1 AI77719"],"award-info":[{"award-number":["RO1 AI77719"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R21 AI128556"],"award-info":[{"award-number":["R21 AI128556"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Lassa virus (LASV), a mammarenavirus, infects an estimated 100,000\u2013300,000 individuals yearly in western Africa and frequently causes lethal disease. Currently, no LASV-specific antivirals or vaccines are commercially available for prevention or treatment of Lassa fever, the disease caused by LASV. The development of medical countermeasure screening platforms is a crucial step to yield licensable products. Using reverse genetics, we generated a recombinant wild-type LASV (rLASV-WT) and a modified version thereof encoding a cleavable green fluorescent protein (GFP) as a reporter for rapid and quantitative detection of infection (rLASV-GFP). Both rLASV-WT and wild-type LASV exhibited similar growth kinetics in cultured cells, whereas growth of rLASV-GFP was slightly impaired. GFP reporter expression by rLASV-GFP remained stable over several serial passages in Vero cells. Using two well-characterized broad-spectrum antivirals known to inhibit LASV infection, favipiravir and ribavirin, we demonstrate that rLASV-GFP is a suitable screening tool for the identification of LASV infection inhibitors. Building on these findings, we established a rLASV-GFP-based high-throughput drug discovery screen and an rLASV-GFP-based antibody neutralization assay. Both platforms, now available as a standard tool at the IRF-Frederick (an international resource), will accelerate anti-LASV medical countermeasure discovery and reduce costs of antiviral screens in maximum containment laboratories.<\/jats:p>","DOI":"10.3390\/v10110655","type":"journal-article","created":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T03:41:31Z","timestamp":1542944491000},"page":"655","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Recombinant Lassa Virus Expressing Green Fluorescent Protein as a Tool for High-Throughput Drug Screens and Neutralizing Antibody Assays"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1101-0920","authenticated-orcid":false,"given":"Y\u00edngy\u00fan","family":"Ca\u00ec","sequence":"first","affiliation":[{"name":"Integrated Research Facility at Fort Detrick (IRF-Frederick), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), B-8200 Research Plaza, Fort Detrick, Frederick, MD 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbial Science, The Scripps Research Institute (TSRI), 10550 North Torrey Pines Rd., La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett F.","family":"Beitzel","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases (USAMRIID), 1425 Porter Street, Fort Detrick, Frederick, MD 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu\u012bq\u00ecng","family":"Y\u00fa","sequence":"additional","affiliation":[{"name":"Integrated Research Facility at Fort Detrick (IRF-Frederick), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), B-8200 Research Plaza, Fort Detrick, Frederick, MD 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena N.","family":"Postnikova","sequence":"additional","affiliation":[{"name":"Integrated Research Facility at Fort Detrick (IRF-Frederick), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), B-8200 Research Plaza, Fort Detrick, Frederick, MD 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Cubitt","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbial Science, The Scripps Research Institute (TSRI), 10550 North Torrey Pines Rd., La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Evans","family":"DeWald","sequence":"additional","affiliation":[{"name":"Integrated Research Facility at Fort Detrick (IRF-Frederick), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), B-8200 Research Plaza, Fort Detrick, Frederick, MD 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheli R.","family":"Radoshitzky","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases (USAMRIID), 1425 Porter Street, Fort Detrick, Frederick, MD 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bollinger","sequence":"additional","affiliation":[{"name":"Integrated Research Facility at Fort Detrick (IRF-Frederick), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), B-8200 Research Plaza, Fort Detrick, Frederick, MD 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"Jahrling","sequence":"additional","affiliation":[{"name":"Integrated Research Facility at Fort Detrick (IRF-Frederick), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), B-8200 Research Plaza, Fort Detrick, Frederick, MD 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo F.","family":"Palacios","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases (USAMRIID), 1425 Porter Street, Fort Detrick, Frederick, MD 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan C.","family":"De la Torre","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbial Science, The Scripps Research Institute (TSRI), 10550 North Torrey Pines Rd., La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7800-6045","authenticated-orcid":false,"given":"Jens H.","family":"Kuhn","sequence":"additional","affiliation":[{"name":"Integrated Research Facility at Fort Detrick (IRF-Frederick), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), B-8200 Research Plaza, Fort Detrick, Frederick, MD 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,11,20]]},"reference":[{"key":"ref_1","unstructured":"(2018, October 09). National Institute of Allergy and Infectious Diseases (NIAID), NIAID Category A, B, and C Priority Pathogens, Available online: https:\/\/www.niaid.nih.gov\/research\/emerging-infectious-diseases-pathogens."},{"key":"ref_2","unstructured":"(2018, October 09). US Department of Health and Human Services (DHHS); Centers for Disease Control and Prevention (CDC); US Department of Agriculture (USDA) Select Agents and Toxins List, Available online: https:\/\/www.selectagents.gov\/selectagentsandtoxinslist.html."},{"key":"ref_3","unstructured":"(2018, October 09). US Department of Health and Human Services (DHHS); Centers for Disease Control and Prevention (CDC); National Institutes of Health (NIH), Biosafety in Microbiological and Biomedical Laboratories (BMBL) 5th Edition, Available online: https:\/\/www.cdc.gov\/biosafety\/publications\/bmbl5\/."},{"key":"ref_4","unstructured":"(2018, October 09). World Health Organization (WHO), List of Blueprint Priority Diseases. Available online: http:\/\/www.who.int\/blueprint\/priority-diseases\/en\/."},{"key":"ref_5","unstructured":"Frame, J.D., Baldwin, J.M., Gocke, D.J., and Troup, J.M. Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings. Am. J. Trop. Med. Hyg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/trstmh\/trv047","article-title":"Mapping the zoonotic niche of Lassa fever in Africa","volume":"109","author":"Mylne","year":"2015","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1016\/S0140-6736(17)32092-5","article-title":"Local, national, and regional viral haemorrhagic fever pandemic potential in Africa: A multistage analysis","volume":"390","author":"Pigott","year":"2017","journal-title":"Lancet"},{"key":"ref_8","unstructured":"(2018, October 09). Centers for Disease Control and Prevention (CDC), Lassa fever, Available online: https:\/\/www.cdc.gov\/vhf\/lassa\/pdf\/factsheet.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2105\/AJPH.2017.304186","article-title":"Mortality among confirmed Lassa fever cases during the 2015\u20132016 outbreak in Nigeria","volume":"108","author":"Buba","year":"2018","journal-title":"Am. J. Public Health"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e1011-6","DOI":"10.1016\/j.ijid.2013.05.015","article-title":"Containing a Lassa fever epidemic in a resource-limited setting: Outbreak description and lessons learned from Abakaliki, Nigeria (January-March 2012)","volume":"17","author":"Ajayi","year":"2013","journal-title":"Int. J. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/trstmh\/tru009","article-title":"Constraints in the diagnosis and treatment of Lassa Fever and the effect on mortality in hospitalized children and women with obstetric conditions in a rural district hospital in Sierra Leone","volume":"108","author":"Dahmane","year":"2014","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S0140-6736(18)30432-X","article-title":"Lassa fever in Nigeria: The great unknown","volume":"391","author":"Burki","year":"2018","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/d41586-018-03171-y","article-title":"Deadly Lassa-fever outbreak tests Nigeria\u2019s revamped health agency","volume":"555","author":"Maxmen","year":"2018","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1126\/science.359.6381.1201","article-title":"Nigeria hit by unprecedented Lassa fever outbreak","volume":"359","author":"Roberts","year":"2018","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa1804498","article-title":"Genomic analysis of Lassa virus during an increase in cases in Nigeria in 2018","volume":"379","author":"Siddle","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_16","unstructured":"(2018, November 13). Nigeria Centre for Disease Control (NCDC), An update of Lassa fever outbreak in Nigeria, Available online: https:\/\/ncdc.gov.ng\/diseases\/sitreps\/?cat=5&name=An%20update%20of%20Lassa%20fever%20outbreak%20in%20Nigeria."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.185.4147.263","article-title":"Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone","volume":"185","author":"Monath","year":"1974","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0140-6736(79)90790-6","article-title":"Experimental Lassa fever virus infection successfully treated with ribavirin","volume":"1","author":"Stephen","year":"1979","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.3201\/eid1612.100994","article-title":"Ribavirin for Lassa fever postexposure prophylaxis","volume":"16","author":"Hadi","year":"2010","journal-title":"Emerg. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/cid\/cix406","article-title":"Favipiravir and ribavirin treatment of epidemiologically linked cases of Lassa fever","volume":"65","author":"Raabe","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s00705-015-2418-y","article-title":"Past, present, and future of arenavirus taxonomy","volume":"160","author":"Radoshitzky","year":"2015","journal-title":"Arch. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Shapshak, P., Sinnott, T.J., Somboonwit, C., and Kuhn, H.J. (2015). Arenaviruses. Global Virology I\u2014Identifying and Investigating Viral Diseases, Springer New York.","DOI":"10.1007\/978-1-4939-2410-3"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.antiviral.2016.10.007","article-title":"Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems","volume":"136","author":"Welch","year":"2016","journal-title":"Antiviral Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5840","DOI":"10.1016\/j.bmcl.2013.08.103","article-title":"Lead optimization of an acylhydrazone scaffold possessing antiviral activity against Lassa virus","volume":"23","author":"Burgeson","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/jmv.24705","article-title":"A cell-based high-throughput protocol to screen entry inhibitors of highly pathogenic viruses with traditional Chinese medicines","volume":"89","author":"Yang","year":"2017","journal-title":"J. Med. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/978-1-4939-6981-4_29","article-title":"Retrovirus-based surrogate systems for BSL-2 high-throughput screening of antivirals targeting BSL-3\/4 hemorrhagic fever-causing viruses","volume":"Volume 1604","author":"Salvato","year":"2018","journal-title":"Hemorrhagic Fever Viruses: Methods and Protocols"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"13B.3.1","DOI":"10.1002\/0471141755.ph13b03s51","article-title":"High-throughput screening of viral entry inhibitors using pseudotyped virus","volume":"51","author":"Basu","year":"2010","journal-title":"Curr. Protoc. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.bmcl.2012.11.095","article-title":"Discovery and optimization of potent broad-spectrum arenavirus inhibitors derived from benzimidazole","volume":"23","author":"Dai","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1016\/j.vaccine.2017.07.101","article-title":"An LASV GPC pseudotyped virus based reporter system enables evaluation of vaccines in mice under non-BSL-4 conditions","volume":"35","author":"Li","year":"2017","journal-title":"Vaccine"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Safronetz, D., Mire, C., Rosenke, K., Feldmann, F., Haddock, E., Geisbert, T., and Feldmann, H. (2015). A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0003736"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"13793","DOI":"10.1128\/JVI.78.24.13793-13803.2004","article-title":"Replicon system for Lassa virus","volume":"78","author":"Hass","year":"2004","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1099\/vir.0.81667-0","article-title":"Arenavirus Z protein as an antiviral target: Virus inactivation and protein oligomerization by zinc finger-reactive compounds","volume":"87","author":"Djavani","year":"2006","journal-title":"J. Gen. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1128\/JVI.03757-13","article-title":"A host-oriented inhibitor of Junin Argentine hemorrhagic fever virus egress","volume":"88","author":"Lu","year":"2014","journal-title":"J. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/2049-632X.12171","article-title":"The NIAID Integrated Research Facility at Frederick, Maryland: A unique international resource to facilitate medical countermeasure development for BSL-4 pathogens","volume":"71","author":"Jahrling","year":"2014","journal-title":"Pathog. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"10908","DOI":"10.1128\/JVI.01433-13","article-title":"Mice lacking functional STAT1 are highly susceptible to lethal infection with Lassa virus","volume":"87","author":"Yun","year":"2013","journal-title":"J. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"10924","DOI":"10.1128\/JVI.01587-15","article-title":"Identification and mechanism of action of a novel small-molecule inhibitor of arenavirus multiplication","volume":"89","author":"Ngo","year":"2015","journal-title":"J. Virol."},{"key":"ref_37","first-page":"e52317","article-title":"Safety precautions and operating procedures in an (A)BSL-4 laboratory: 1. Biosafety level 4 suit laboratory suite entry and exit procedures","volume":"116","author":"Krisztina","year":"2016","journal-title":"J. Vis. Exp."},{"key":"ref_38","first-page":"e53600","article-title":"Safety precautions and operating procedures in an (A)BSL-4 laboratory: 2. General practices","volume":"116","author":"Mazur","year":"2016","journal-title":"J. Vis. Exp."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-1-4939-6964-7_13","article-title":"Lassa virus reverse genetics","volume":"1602","author":"Paessler","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"11544","DOI":"10.1038\/ncomms11544","article-title":"Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits","volume":"7","author":"Robinson","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/infdis\/jiv522","article-title":"Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of Lassa fever","volume":"213","author":"Oestereich","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJM198601023140104","article-title":"Lassa fever. Effective therapy with ribavirin","volume":"314","author":"McCormick","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"14775","DOI":"10.1038\/srep14775","article-title":"The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset","volume":"5","author":"Safronetz","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/nm.4396","article-title":"Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever","volume":"23","author":"Mire","year":"2017","journal-title":"Nat. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1369\/jhc.7A7180.2007","article-title":"A comparative analysis of novel fluorescent proteins as reporters for gene transfer studies","volume":"55","author":"Bell","year":"2007","journal-title":"J. Histochem. Cytochem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.antiviral.2017.11.004","article-title":"Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens","volume":"149","author":"Tong","year":"2018","journal-title":"Antiviral Res."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Iwasaki, M., Minder, P., Ca\u00ec, Y., Kuhn, J.H., Yates, J.R., Torbett, B.E., and de la Torre, J.C. (2018). Interactome analysis of the lymphocytic choriomeningitis virus nucleoprotein in infected cells reveals ATPase Na+\/K+ transporting subunit \u03b1 1 and prohibitin as host-cell factors involved in the life cycle of mammarenaviruses. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1006892"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Wang, M.K.-M., Ren, T., Liu, H., Lim, S.-Y., Lee, K., Honko, A., Zhou, H., Dyall, J., Hensley, L., and Gartin, A.K. (2018). Critical role for cholesterol in Lassa fever virus entry identified by a novel small molecule inhibitor targeting the viral receptor LAMP1. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1007322"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.antiviral.2011.05.006","article-title":"Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus","volume":"91","author":"Neyts","year":"2011","journal-title":"Antiviral Res."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/10\/11\/655\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:30:53Z","timestamp":1760196653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/10\/11\/655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,20]]},"references-count":49,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,11]]}},"alternative-id":["v10110655"],"URL":"https:\/\/doi.org\/10.3390\/v10110655","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,20]]}}}